Figures computed from official regulatory filings — .
Analysttarget 49 USD (+37%) · consensus 4.75/5 · 4 buy · 0 hold · 0 sell
Ownershipinsiders 1.8% · institutions 102.73% · short 11.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Indivior Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
10 buys3 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Anderson Woodrow D | Buy | $53.5K | conv 40 | SEC |
| Anderson Woodrow D | Buy | $54.4K | conv 51First in 12mo | SEC |
| Heidbreder Christian | Sell | $764.6K | SEC |
| Ciaffoni Joseph | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Ciaffoni Joseph | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Ciaffoni Joseph | Other | $23.5M | Unusual size | SEC |
| Heidbreder Christian | Sell | $707.4K | SEC |
| Preblick Ryan | Sell | $1.4M | SEC |
| Wheadon David E. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kingsley Stuart A | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Stejbach Marktrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Thompson Juliet | Other | $42.8K | SEC |
| Ryan Barbara | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Thompson Juliet | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| NINIVAGGI DANIEL Atrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Humphreys Keith | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Preblick Ryan | Other | $88.4K | SEC |
| Preblick Ryan | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Preblick Ryan | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Ryan Barbara | Buy | $248.7 | conv 36Cluster | SEC |
| Ryan Barbara | Buy | $1K | conv 44Cluster | SEC |
| Kingsley Stuart A | Buy | $30K | conv 58ClusterFirst in 12mo | SEC |
| Anderson Woodrow D | Other | $85.8K | SEC |
| Preblick Ryan | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Heidbreder Christian | Other | $1.5M | SEC |